Moreover, some SHP2-AIs also display unexpected activity against the so-called RAS bypass cancers, which harbor RAS or RAF mutations known to be independent of upstream signaling from SHP2 (23, 26, 27, 33, 38). This evidence concerns the gene PTPN11 and cancer.